Intra-Arterial Drug and Light Delivery for Photodynamic Therapy Using Visudyne®: Implication for Atherosclerotic Plaque Treatment.
Photodynamic therapy (PDT), which is based on the activation of photosensitizers with light, can be used to reduce plaque burden. We hypothesized that intra-arterial photosensitizer administration and photo-activation will lead to high and rapid accumulation within the plaque with reduced systemic adverse effects. Thus, this "intra-arterial" PDT would be expected to have less side effects and due to the short time involved would be compatible with percutaneous coronary interventions.


OBJECTIVE
We characterized the dose-dependent uptake and efficacy of intra-arterial PDT using Liposomal Verteporfin (Visudyne®), efficient for cancer-PDT but not tested before for PDT of atherosclerosis.


RESULTS
Visudyne® (100, 200, and 500 ng/ml) was perfused for 5-30 min in atherosclerotic aorta isolated from ApoE(-/-) mice. The fluorescence Intensity (FI) after 15 min of Visudyne® perfusion increased with doses of 100 (FI-5.5 ± 1.8), 200 (FI-31.9 ± 1.9) or 500 ng/ml (FI-42.9 ± 1.2). Visudyne® (500 ng/ml) uptake also increased with the administration time from 5 min (FI-9.8 ± 2.5) to 10 min (FI-23.3 ± 3.0) and 15 min (FI-42.9 ± 3.4) before reaching saturation at 30 min (FI-39.3 ± 2.4) contact. Intra-arterial PDT (Fluence: 100 and 200 J/cm(2), irradiance-334 mW/cm(2)) was applied immediately after Visudyne® perfusion (500 ng/ml for 15 min) using a cylindrical light diffuser coupled to a diode laser (690 nm). PDT led to an increase of ROS (Dihydroethidium; FI-6.9 ± 1.8, 25.3 ± 5.5, 43.4 ± 13.9) and apoptotic cells (TUNEL; 2.5 ± 1.6, 41.3 ± 15.3, 58.9 ± 6%), mainly plaque macrophages (immunostaining; 0.3 ± 0.2, 37.6 ± 6.4, 45.3 ± 5.4%) respectively without laser irradiation, or at 100 and 200 J/cm(2). Limited apoptosis was observed in the medial wall (0.5 ± 0.2, 8.5 ± 4.7, 15.3 ± 12.7%). Finally, Visudyne®-PDT was found to be associated with reduced vessel functionality (Myogram).


CONCLUSIONS
We demonstrated that sufficient accumulation of Visudyne® within plaque could be achieved in short-time and therefore validated the feasibility of local intravascular administration of photosensitizer. Intra-arterial Visudyne®-PDT preferentially affected plaque macrophages and may therefore alter the dynamic progression of plaque development.
Cardiology, Department of Medicine, University and Hospital of Fribourg Fribourg, Switzerland.
Manish
M
Jain
Medical Photonics Group, LCOM-ISIC, Swiss Federal Institute of Technology (EPFL) Lausanne, Switzerland.
Matthieu
M
Zellweger
Cardiology, Department of Medicine, University and Hospital of Fribourg Fribourg, Switzerland.
Aurélien
A
Frobert
Cardiology, Department of Medicine, University and Hospital of Fribourg Fribourg, Switzerland.
Jérémy
J
Valentin
Medical Photonics Group, LCOM-ISIC, Swiss Federal Institute of Technology (EPFL) Lausanne, Switzerland.
Hubert
H
van den Bergh
Medical Photonics Group, LCOM-ISIC, Swiss Federal Institute of Technology (EPFL) Lausanne, Switzerland.
Georges
G
Wagnières
Cardiology, Department of Medicine, University and Hospital of Fribourg Fribourg, Switzerland.
Stéphane
S
Cook
Cardiology, Department of Medicine, University and Hospital of Fribourg Fribourg, Switzerland.
Marie-Noelle
MN
Giraud
apoptosis; atherosclerosis; macrophage; photodynamic therapy; verteporfin; visudyne®
Lasers Surg Med. 2001;28(4):381-8
11344521
Jpn Circ J. 1999 May;63(5):387-93
10943619
Lasers Surg Med. 1990;10(5):485-8
2146455
Arterioscler Thromb Vasc Biol. 2015 Jun;35(6):1445-55
25908764
J Immunol. 2002 Nov 15;169(10):5866-73
12421969
Lasers Surg Med. 1998;23 (5):263-73
9888322
J Geriatr Cardiol. 2012 Sep;9(3):305-17
23097661
Nat Med. 2002 Nov;8(11):1249-56
12411952
Biol Proced Online. 2014 Mar 31;16(1):6
24685068
Nat Methods. 2016 Mar;13(3):263-8
26808669
J Photochem Photobiol B. 2000 Mar;55(1):56-62
10877068
Cancer. 1995 Jun 1;75(11):2768-78
7743484
Vasc Health Risk Manag. 2008;4(2):341-53
18561510
Free Radic Biol Med. 2003 Apr 15;34(8):1070-7
12684092
Proc Natl Acad Sci U S A. 2004 Mar 30;101(13):4578-83
15070760
Circ Res. 2015 Aug 28;117(6):513-24
26208651
J Am Coll Cardiol. 2008 Sep 16;52(12):1024-32
18786486
J Biomed Opt. 2006 Mar-Apr;11(2):021008
16674183
Circulation. 2006 Feb 28;113(8):1108-13
16490815
J Biomech. 2002 Jun;35(6):757-65
12020995
Photochem Photobiol. 1996 Nov;64(5):758-63
8931372
Br J Cancer. 1994 May;69(5):833-9
8180011
N Engl J Med. 2001 Aug 16;345(7):494-502
11519503
Eur J Vasc Endovasc Surg. 1996 Jan;11(1):19-28
8564482
Photochem Photobiol. 1998 Sep;68(3):382-7
9747593
Invest Ophthalmol Vis Sci. 2008 Jul;49(7):3158-63
18579764
Arterioscler Thromb Vasc Biol. 2001 May;21(5):759-64
11348871
Br J Cancer. 2003 Dec 15;89(12):2320-6
14676813
Heart. 2005 Apr;91(4):535-6
15772225
J Photochem Photobiol B. 2011 Jan 10;102(1):26-31
20875747
Heart. 2006 Aug;92(8):1138-44
16399853
Cancer Res. 1993 Jun 1;53(11):2548-52
8495418
J Endovasc Surg. 1995 Nov;2(4):365-71
9234156
Int J Nanomedicine. 2015 May 22;10 :3719-36
26045663
Nat Immunol. 2011 Mar;12(3):204-12
21321594
PLoS One. 2013 Oct 17;8(10):e77037
24146955
Cardiovasc Res. 2001 Feb 1;49(2):449-55
11164855
Clin Cardiol. 2011 Oct;34(10):588-92
21932326
J Natl Cancer Inst. 1987 Dec;79(6):1327-32
3480384
Br J Dermatol. 2014 Dec;171(6):1298-9
25523262
Br J Pharmacol. 1997 May;121(1):63-70
9146888
Heart. 2007 Feb;93(2):258-65
17228079
Vasc Health Risk Manag. 2012;8:549-61
23049260
Anat Rec (Hoboken). 2013 Mar;296(3):378-81
23382140
Photochem Photobiol. 1997 May;65(5):877-83
9155261
Cardiovasc Pathol. 2005 Jul-Aug;14(4):181-4
16009315
Am J Pathol. 2001 Jul;159(1):305-11
11438477
Cancer Biol Ther. 2008 Dec;7(12):1875-84
18981733
Circulation. 2001 Mar 27;103(12 ):1702-8
11274000
Brain Res Brain Res Protoc. 2000 Jul;5(3):305-11
10906497
Chem Biol Drug Des. 2012 Apr;79(4):459-69
22145586
Trends Cardiovasc Med. 2014 Oct;24(7):305-13
25240980
Photochem Photobiol. 1993 Apr;57(4):670-4
8506397
Circulation. 2003 Sep 16;108(11):1310-5
12939212
J Control Release. 2010 Jun 15;144(3):288-95
20202474
Antioxid Redox Signal. 2010 Mar 1;12(5):675-82
19747062
Int J Cancer. 1995 Oct 9;63(2):198-204
7591204
Pharmacol Res. 2011 Sep;64(3):274-82
21497197
J Cutan Med Surg. 2001 Jan-Feb;5(1):8-13
11281435
Lasers Surg Med. 1988;8(3):294-300
2969070
J Cardiovasc Pharmacol Ther. 2016 Mar;21(2):187-200
26240073
Mol Aspects Med. 2001 Aug-Oct;22(4-5):189-216
11679166
Am J Health Syst Pharm. 2015 Oct 1;72(19):1623-9
26386103
Cell Metab. 2009 May;9(5):474-81
19416717
Front Immunol. 2014 Oct 17;5:514
25368618
Lab Invest. 1997 Feb;76(2):257-66
9042162
Med Mol Morphol. 2005 Dec;38(4):225-32
16378231
Cardiovasc Revasc Med. 2017 Jan - Feb;18(1):10-15
27477306